Inmed Pharmaceuticals Inc (IMLFF) 0.1275 $IMLFF InMed

New Post Public Reply Private Reply Replies (0) Message Board

Oct 11, 2015 at 6:52 AM

Inmed Pharmaceuticals Inc (IMLFF) 0.1275 $IMLFF

InMed Appoints Paul Brennan as President & Chief Executive Officer
Marketwired - Thu Sep 03, 5:00AM CDT
InMed Pharmaceuticals Inc. ("InMed" or "the Company"

(CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today that Paul Brennan, a 25-year veteran of the life sciences industry, has joined InMed as President & CEO, effective September 14, 2015. Mr. Brennan succeeds Craig Schneider who will remain on the board of directors.

InMed Commences Development of Proprietary Drug Delivery System
Marketwired - Wed Sep 02, 4:01AM CDT
InMed Pharmaceuticals Inc. ("InMed"

(CSE: IN)(OTCQB: IMLFF) is pleased to announce it has initiated testing of a novel nanoparticle based delivery system for INM-750 which will be used for clinical formulations. INM-750 is a proprietary phytocannabinoid based compound for the treatment of epidermolysis bullosa simplex (EBS), a rare genetically inherited skin disorder (See NR News Release May 26, 2015 and August 6, 2015).

InMed Appoints Paul Brennan to the Board of Directors
Marketwired - Tue Aug 25, 4:00AM CDT
InMed Pharmaceuticals Inc. ("InMed" or "the Company"

(CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today the appointment of Paul Brennan to the Company's Board of Directors. Mr. Brennan brings more than 25 years of experience in building, leading and advising top-performing pharmaceutical and biotechnology companies in Europe, Canada and the United States.
ABUS: 6.12 (-0.14), TKMR: 10.83 (+0.58)

InMed Pharmaceuticals Announces Progress in Orofacial Pain Program
Marketwired - Thu Aug 20, 7:01AM CDT
InMed Pharmaceuticals Inc. ("InMed"

(CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announces today the successful completion and validation of preclinical pain modelling.

InMed Announces Positive In-Vitro Study Results of INM-750 Targeting Epidermolysis Bullosa Simplex (EBS)
Marketwired - Thu Aug 06, 4:01AM CDT
InMed Pharmaceuticals Inc. ("InMed"

(CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today that it has obtained positive response from its pre-clinical research on INM-750 tested in various in vitro assays. The INM-750 is a proprietary phytocannabinoid based compound for the treatment of epidermolysis bullosa simplex (EBS), a rare genetically inherited skin disorder. INM-750 is designed to modulate skin growth, differentiation and inflammation that are signature characteristics of EBS.

Epidermolysis Bullosa - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jxnlsl/epidermolysis) has announced the addition of the "Epidermolysis Bullosa - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epidermolysis Bullosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Fibrocell Science, Inc. - GlaxoSmithKline plc - InMed Pharmaceuticals Inc. - RegeneRx Biopharmaceuticals, Inc. - Scioderm, Inc. - Shire Plc - TWi Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/jx...dermolysis
FCSC: 4.18 (+0.31), SHPG: 200.90 (-1.85), GSK: 40.22 (+0.06)

Epidermolysis Bullosa Therapeutic Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Thu Jun 25, 8:31PM CDT
The report "Epidermolysis Bullosa - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Epidermolysis Bullosa. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/epidermolysi...eport.html .
SHPG: 200.90 (-1.85), GSK: 40.22 (+0.06)

InMed Pharmaceuticals Inc. (IMLFF) to Present at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on June 10
GlobeNewswire - Thu Jun 04, 7:01AM CDT
InMed Pharmaceuticals Inc. (OTCMKTS:IMLFF), a clinical stage biopharmaceutical company, will be presenting at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on Wednesday, June 10. The event is a gathering of the brightest emerging growth small-cap and pre-IPO companies to present and network with an exclusive group of top-level institutional investors.

InMed Adds Chronic Obstructive Pulmonary Disease (COPD) Program to Therapeutic Pipeline
Marketwired - Wed Jun 03, 5:00AM CDT
InMed Pharmaceuticals Inc. ("InMed"

(CSE: IN)(OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, announced it has initiated a program to identify and evaluate cannabinoid compounds for the treatment of chronic obstructive pulmonary disease (COPD). Initial drug discovery and preclinical development is currently underway in collaboration with members of the Department of Anesthesiology, Pharmacology & Therapeutics at the University of British Columbia.

InMed Pharmaceuticals Files Provisional Patent Covering Novel Compounds for Treating Epidermolysis Bullosa Simplex (EBS)
PR Newswire - Tue May 26, 5:00AM CDT
InMed Pharmaceuticals Inc. ("InMed"

(CSE: IN; OTCQB: IMLFF), announced today that it has filed a provisional patent application with the United States Patent and Trademark Office ("USPTO"

relating to the treatment of Epidermolysis Bullosa Simplex (EBS) using novel formulations of natural cannabinoid compounds developed by InMed.

InMed Pharmaceuticals Files Provisional Patent Application for Treating Eye Disease - Video News Alert on InvestmentPitch.com
Newsfile Corp - Wed May 13, 10:32AM CDT
full story)

InMed Pharmaceuticals Files Provisional Patent for Compositions Treating Eye Diseases
Marketwired - Tue May 12, 11:45AM CDT
InMed Pharmaceuticals Inc. ("InMed" or the "Company"

(CSE: IN)(OTCQB: IMLFF), announced today that it has filed a provisional patent application with the United States Patent and Trademark Office ("USPTO"

relating to the treatment of eye diseases.

CARERS Act Likely to Intensify Awareness for DUI Laws and Need for Marijuana Breathalyzer
ACCESSWIRE - Wed May 06, 7:01AM CDT
WHITFISH, MT / ACCESSWIRE / May 6, 2015 / The marijuana industry received some substantial news in March with bi-partisan support in both chambers of Congress that would facilitate growth for the industry by loosening federal marijuana laws. Rep. Steve Cohen (D-TN) with co-sponsor Rep. Don Young (R-AK) filed the House version of the CARERS Act (short for Compassionate Access, Research Expansion, and Respect States) and six additional House members co-sponsoring the bill have now joined them. The Senate version, filed by Senators Cory Booker (D-NJ), Rand Paul (R-KY), and Kirsten Gillibrand (D-NY) earlier in the month has added two additional senators as co-sponsors. The CARERS Act aims to resolve several problematic regulations with marijuana, including allowing interstate commerce, opening the banking system to marijuana dispensaries, permitting the Veterans Administration to recommend medical marijuana to vets, rescheduling marijuana to Schedule 2, allowing states to legalize marijuana for medical use without federal interference and eliminate barriers to medical marijuana research. If passed into law, it will benefit a wide array of marijuana companies, including cannabinoid-based drug developers like GW Pharmaceuticals (NASDAQ: GWPH), Insys Therapeutics (NASDAQ: INSY) and InMed Pharmaceuticals (OTCQB: IMLFF) (CSE: IN).
INSY: 25.65 (+0.64), GWPH: 87.75 (+0.45), ABBV: 55.64 (-0.40)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

GPRO, BWMN, DV Deals Scrutinized: Shareholder Impact?

Questioning Fairness in Shareholder Deals There's a storm brewing in the world of mergers and acquisitions—and it's casting a shadow over the likes of GoPro, Bowman Consulting Group, and DoubleVerify. All three are under the legal microscope, with Halper Sadeh LLC, an investor rights firm, probing potential breaches of fiduciary responsibilities. It's always a...

MIAX Launches New Fertilizer Futures Amid Market Fluctuations

MIAX Sets Sights on Fertilizer Futures Out of the blue, we’ve got MIAX—one of the major players in financial markets—tossing their hat into the ring with fertilizer futures. They aren’t just playing around; they’ve launched four new physically-settled fertilizer futures contracts. You might wonder, why fertilizers? Hang tight, I'll tell you. MIAX is tapping into...

Heineken Hit with €111M Judgment—A Precedent Set

A Brew of Legal Consequences for Heineken If this isn't a financial wake-up call for the brewing giant, I don't know what is. In the latest twist of corporate accountability, the Amsterdam District Court has ordered Heineken and its Greek subsidiary, Athenian Brewery, to cough up a whopping €111 million. And we're not just talking pocket change—this ruling speaks...

Dr. Anke Otto-Wolf's BEFORE Framework Revolutionizes SEL

Teaching Kids to Catch Themselves: Introducing BEFORE Calling October Bullying Prevention Month seems quaint when you consider how often kids get shoved around, physically or emotionally. What’s surprising is how one simple word, ‘BEFORE,’ might just be the game-changer. Dr. Anke Otto-Wolf is betting big on it by unveiling the BEFORE Framework™. Imagine kids...

Expert Vet Advice: When Pet Surgery Is Necessary

Tough Calls: Knowing When Your Pet Needs Surgery Alright, when it comes to our furry companions, knowing when to opt for surgery ain't no walk in the park. It's a tricky balance, folks. Is that lump something to worry about? Will that limp heal on its own? HelloNation's recent piece dives into these questions, leveraging the expertise of Veterinarian Lorrie Riggs from...

Advent Expands Middle East Presence with Abu Dhabi Office

Advent's Bold Middle East Move Alright, let's get one thing straight: Advent isn't just tiptoeing into the Middle East—they're making a splash. On October 21, 2026, Advent unfurled a shiny new office in Abu Dhabi's ADGM, a prime international financial center. This ain't some tentative handshake. This move boldly asserts their ambition to deepen their foothold with...

Long March Unity: Defying Odds with Shared Conviction

Unlikely Unity Amidst Adversity Imagine facing a path so treacherous that every step could mean your last. That was the Long March for the Red Army—a grueling test not just of endurance, but of unity. This is the kind of story that makes you sit up and think about what drives people to stick together when everything is falling apart. The Red Army faced hellish...

Bolt Teams with NVIDIA for Europe AV Expansion

Racing Towards an Autonomous Future Well, hold onto your seats because the European roads will soon witness one hell of a technological trip—with an autonomous twist. Bolt, in cahoots with NVIDIA and Lucid, is plotting to roll out a massive fleet of autonomous vehicles just gearing up to hit the streets. The project's kicking off in Madrid in 2027 and aims to sprinkle...

United Bancshares Delivers Strong Q3 Results, Boosts Dividend

United Bancshares Shines in Third Quarter 2026 You don't always get handed a report that makes you grin over your coffee, but United Bancshares, Inc. (OTCQX:UBOH) has pulled off a strong showing for the third quarter of 2026. The bank's been on a tear, driving home an impressive $5.2 million in net income—that's $1.90 per share. Compare that against last year's $3.0...

Salvi's Legal Titans Shine: 19 Super Lawyers Honored

A Salute to Legal Prowess in Illinois Dusting off the headlines once again, Salvi, Schostok & Pritchard have played a winning hand, proving they're no pushover in Illinois' legal scene with a whopping 19 attorneys honored as Super Lawyers and Rising Stars for 2027. This isn't just any badge. We're talking about a pat on the back from peers in a fiercely competitive...